Charles River Laboratories CRL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Business | |||||
| DSA | $2.4B-2.0% | $2.45B-6.3% | $2.62B— | —— | |
| Manufacturing | $766.41M-0.4% | $769.33M+6.6% | $721.44M— | —— | |
| RMS | $846.08M+2.0% | $829.38M+4.7% | $792.34M— | —— | |
| Total by Business | |||||
| DSA | $51.68M+31.4% | $39.34M+143% | $16.18M— | —— | |
| Manufacturing | $18.26M+41.8% | $12.87M+40.9% | $9.14M— | —— | |
| RMS | $18.71M-57.4% | $43.91M+1,162% | $3.48M— | —— | |
| Cost of revenue (excluding amortization of intangible assets) by Business | |||||
| DSA | $1.69B-0.7% | $1.7B+1.3% | $1.68B+3.6% | $1.62B— | |
| Manufacturing | $429.84M-2.4% | $440.51M-0.2% | $441.41M+0.3% | $440.04M— | |
| RMS | $576.25M-0.7% | $580.49M+13.8% | $509.97M+11.9% | $455.61M— | |
| Operating Income (Loss) by Business | |||||
| DSA | $424.56M-4.1% | $442.51M-27.0% | $606.08M— | —— | |
| Manufacturing | -$184.28M-158% | -$71.45M-181% | $88.33M— | —— | |
| SG&A by Business | |||||
| DSA | $239.77M-3.7% | $249.1M-5.6% | $263.77M+23.3% | $213.87M— | |
| Manufacturing | $142.1M+7.0% | $132.8M-9.2% | $146.31M+5.2% | $139.03M— | |
| RMS | $101.53M-8.5% | $110.98M+4.7% | $105.97M+3.1% | $102.8M— | |
| Foreign exchange by Business | |||||
| RMS | $14.1M+2,022% | -$734K— | —— | —— | |
| Goodwill, Written off Related to Sale of Business Unit by Business | |||||
| Manufacturing | $0— | —— | —— | —— | |
| RMS | $0— | —— | —— | —— | |
| Capital Expenditures by Business | |||||
| DSA | $132.96M+3.6% | $128.36M-37.4% | $204.89M— | —— | |
| Manufacturing | $41.43M+7.6% | $38.5M-33.8% | $58.13M— | —— | |
| RMS | $38.84M-39.4% | $64.13M+21.4% | $52.82M— | —— | |
| D&A by Business | |||||
| DSA | $174.03M-8.9% | $191.13M+9.4% | $174.72M— | —— | |
| Manufacturing | $140.22M+55.9% | $89.96M+12.5% | $79.98M— | —— | |
| RMS | $81.08M+9.8% | $73.81M+32.8% | $55.57M— | —— | |
| Intangible Amortization by Business | |||||
| DSA | $52.55M-15.9% | $62.51M-11.1% | $70.31M-15.1% | $82.8M— | |
| Manufacturing | $104.78M+99.7% | $52.47M+15.6% | $45.39M+4.6% | $43.42M— | |
| RMS | $21.74M-7.5% | $23.49M+8.1% | $21.74M+6.8% | $20.36M— | |
| Goodwill impairment by Business | |||||
| DSA | $0— | $0— | —— | —— | |
| Manufacturing | $165M-23.3% | $215M— | $0— | $0— | |
| RMS | $0— | $0— | —— | —— | |
| Intangible asset impairment by Business | |||||
| Manufacturing | $108.97M— | $0— | $0— | —— | |
| RMS | $211M— | $0— | $0— | —— | |
| Goodwill, impaired, accumulated impairment loss by Business | |||||
| DSA | $4B0.0% | $4B— | —— | —— | |
| Manufacturing | $1.03B— | —— | —— | —— | |
| Total Revenue by Geography | |||||
| Asia Pacific | $205.02M+4.1% | $196.95M-1.9% | $200.83M+4.1% | $192.84M-13.5% | |
| Canada | $501.03M+3.9% | $482.09M-1.1% | $487.31M+22.1% | $398.98M+17.7% | |
| Europe | $1.1B+2.3% | $1.08B+0.1% | $1.08B+4.3% | $1.03B-0.4% | |
| Other | $64.87M+22.8% | $52.82M+214% | $16.85M+69.2% | $9.96M+36.6% | |
| U.S. | $2.14B-4.4% | $2.24B-4.6% | $2.35B+0.2% | $2.34B+21.1% | |
| Long-Lived Assets by Geography | |||||
| Asia Pacific | $252.26M-8.9% | $276.81M— | —— | —— | |
| Canada | $622.2M+2.4% | $607.41M— | —— | —— | |
| Europe | $1.79B+8.8% | $1.65B— | —— | —— | |
| Other | $161.04M+11.9% | $143.85M— | —— | —— | |
| U.S. | $3.61B-5.0% | $3.8B— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Charles River Laboratories break its business down?
- Charles River Laboratories (CRL) reports total revenue by business across 3 parts — DSA, Manufacturing and RMS. Each is extracted from the segment footnotes and tracked over time.
- Where does Charles River Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Charles River Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
